X4 Pharmaceuticals company info

What does X4 Pharmaceuticals do?
X4 Pharmaceuticals (NASDAQ:XFOR) is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for the treatment of rare diseases and immune system disorders. The company's lead product candidate, mavorixafor, is in late-stage clinical development aimed at treating WHIM syndrome, a rare, inherited, primary immunodeficiency disease, and has potential applications in a broad range of cancer and autoimmune diseases. X4 Pharmaceuticals is dedicated to advancing its pipeline through scientific innovation and rigorous clinical studies, with the objective of improving the lives of patients battling serious diseases. Through its research and development efforts, the company aims to unlock the full potential of its therapies by addressing underserved medical needs.
X4 Pharmaceuticals company media
Company Snapshot

Is X4 Pharmaceuticals a public or private company?

key
Ownership
Public

How many people does X4 Pharmaceuticals employ?

people
Employees
93

What sector is X4 Pharmaceuticals in?

pie chart
Sector
Health Care

Where is the head office for X4 Pharmaceuticals?

location pin
Head Office
Boston, United States

What year was X4 Pharmaceuticals founded?

founded flag
Year Founded
2019
What does X4 Pharmaceuticals specialise in?
/Cancer Therapies /Immunodeficiency Medications /WHIM Syndrome /Clinical Research /Oncology Biotechnology /Targeted Treatments

What are the products and/or services of X4 Pharmaceuticals?

Overview of X4 Pharmaceuticals offerings
Mavorixafor, a CXCR4 antagonist aimed at treating WHIM syndrome and certain cancers.
Clinical trials for the treatment of Severe Congenital Neutropenia with CXCR4 antagonist therapy.
Development of next-generation CXCR4 antagonists for a range of cancers.
Research on CXCR4 inhibitors for the potential treatment of Waldenstrom macroglobulinemia.
Preclinical studies investigating the role of CXCR4 antagonism in multiple myeloma.
Exploration of CXCR4-related therapies for improving hematopoietic stem cell transplantation.

Who is in the executive team of X4 Pharmaceuticals?

X4 Pharmaceuticals leadership team
  • Dr. Paula  Ragan Ph.D.
    Dr. Paula Ragan Ph.D.
    CEO, President & Director
  • Mr. Adam S. Mostafa
    Mr. Adam S. Mostafa
    CFO, Treasurer & Corporate Secretary
  • Dr. Mary  DiBiase Ph.D.
    Dr. Mary DiBiase Ph.D.
    Chief Operating Officer
  • Dr. Richard  Peters M.D., Ph.D.
    Dr. Richard Peters M.D., Ph.D.
    Founder
  • Dr. Renato T. Skerlj Ph.D.
    Dr. Renato T. Skerlj Ph.D.
    Founder
  • Dr. Keith T. Flaherty M.D.
    Dr. Keith T. Flaherty M.D.
    Founder & Member of Corporate Advisory Board
  • Dr. Arthur  Taveras Ph.D.
    Dr. Arthur Taveras Ph.D.
    Chief Scientific Officer
  • Dr. Glenn  Schulman M.P.H., Pharm. D., Pharm.D.
    Dr. Glenn Schulman M.P.H., Pharm. D., Pharm.D.
    Vice President of Investor Relations & Corporate Communications